Published in J Clin Epidemiol on August 01, 1999
Model-Based Assessment of Alternative Study Designs in Pediatric Trials. Part II: Bayesian Approaches. CPT Pharmacometrics Syst Pharmacol (2016) 0.78
On "Bayesian monitoring...". J Clin Epidemiol (1999) 0.75
Design and serendipity in establishing a large cohort with wide dietary intake distributions : the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol (2001) 11.17
Breast cancer clusters in the northeast United States: a geographic analysis. Am J Epidemiol (1997) 5.73
Tables of the number of patients required in clinical trials using the logrank test. Stat Med (1983) 5.34
Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer (1978) 5.25
I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther (2009) 5.01
Common individual antigenic determinants in five of eight BALB-c IgA myeloma proteins that bind phosphoryl choline. J Exp Med (1970) 4.49
On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics (1976) 3.82
Group-specific antigen expression during embryogenesis of the genome of the C-type RNA tumor virus: implications for ontogenesis and oncogenesis. Proc Natl Acad Sci U S A (1970) 3.71
Genetics of a new IgVH (T15 idiotype) marker in the mouse regulating natural antibody to phosphorylcholine. J Exp Med (1974) 3.64
Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res (1978) 3.51
Genetics of immunoglobulins in the mouse. Adv Immunol (1967) 3.14
Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst (1996) 2.98
H-2-linked immune response (Ir) genes. Independent loci for Ir-IgG and Ir-IgA genes. J Exp Med (1972) 2.50
Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis. Oncogene (2008) 2.48
Implications of a new dietary measurement error model for estimation of relative risk: application to four calibration studies. Am J Epidemiol (1999) 2.40
Empirical evidence of correlated biases in dietary assessment instruments and its implications. Am J Epidemiol (2001) 2.33
A mouse IgM allotypic determinant (Igh-6.5) recognized by a monoclonal rat antibody. J Immunol (1981) 2.27
Injuries sustained on "bouncy castles". BMJ (1992) 2.20
Inability of mice with a defect in B-lymphocyte maturation to respond to phosphorycholine on immunogenic carriers. J Exp Med (1977) 2.18
Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res (1999) 2.13
Association of H-2 types with genetic control of immune responsiveness to IgA allotypes in the mouse. Proc Natl Acad Sci U S A (1971) 2.07
Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol (2001) 2.03
Choroid plexus cysts: not associated with Down syndrome. Ultrasound Obstet Gynecol (1996) 2.02
Clonal nature of the immune response to phosphorylcholine. II. Idiotypic specificity and binding characteristics of anti-phosphorylcholine antibodies. J Immunol (1974) 1.95
Multiple individual and cross-specific indiotypes on 13 levan-binding myeloma proteins of BALB/c mice. J Exp Med (1975) 1.94
Serum concentrations and allotypes of immunoglobulins in two lines of mice genetically selected for "high" or "low" antibody synthesis. J Exp Med (1970) 1.93
Histological grade and other prognostic factors in relation to survival of patients with breast cancer. Br J Cancer (1979) 1.92
The CHART trials: Bayesian design and monitoring in practice. CHART Steering Committee. Stat Med (1994) 1.90
The development of a risk-adjusted capitation payment system: the Maryland Medicaid model. J Ambul Care Manage (1998) 1.86
Clonal nature of the immune response to phosphorylcholine. I. Specificity, class, and idiotype of phosphorylcholine-binding receptors on lymphoid cells. J Exp Med (1974) 1.85
Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res (2000) 1.84
Potential impact of genetic testing on cancer prevention trials, using breast cancer as an example. J Natl Cancer Inst (1995) 1.84
A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion. Stat Med (1986) 1.82
Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet (1987) 1.79
Structure of human skeletal keratosulfate. The linkage region. J Biol Chem (1967) 1.77
Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res (1996) 1.77
Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies. Proc Natl Acad Sci U S A (2005) 1.74
Association of H-2 types with genetic control of immune reponsiveness to IgG (gamma2a) allotypes in the mouse. J Exp Med (1972) 1.71
Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr (2000) 1.69
Genetics of mouse antibodies. I. Linkage of the dextran response locus, VH-DEX, to allotype. Eur J Immunol (1975) 1.68
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol (2005) 1.63
The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol (1996) 1.63
Idiotype of inulin-binding antibodies and myeloma proteins controlled by genes linked to the allotype locus of the mouse. J Immunol (1976) 1.62
Interpreting precursor studies: what polyp trials tell us about large-bowel cancer. J Natl Cancer Inst (1994) 1.61
Do adaptive changes in metabolic rate favor weight regain in weight-reduced individuals? An examination of the set-point theory. Am J Clin Nutr (2000) 1.61
Phase specific analysis of herpes zoster associated pain data: a new statistical approach. Stat Med (2001) 1.60
Immune response to levan. I. Kinetics and ontogeny of anti-levan and anti-inulin antibody response and of expression of cross-reactive idiotype. J Immunol (1978) 1.57
Can energy adjustment separate the effects of energy from those of specific macronutrients? Am J Epidemiol (1994) 1.56
Crossing over between genes in the immunoglobulin heavy chain linkage group of the mouse. J Exp Med (1969) 1.56
Mechanism of antidiuretic effect of beta adrenergic stimulation. J Clin Invest (1972) 1.54
Assay of C-type virus infectivity by measurement of RNA-dependent DNA polymerase activity. Virology (1972) 1.53
Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev (1999) 1.49
Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer (1991) 1.49
The use of a Kolmogorov--Smirnov type statistic in testing hypotheses about seasonal variation. J Epidemiol Community Health (1979) 1.49
Murine C-type RNA virus from spontaneous neoplasms: in vitro host range and oncogenic potential. Science (1973) 1.48
Lyb-7, a new B cell alloantigen controlled by genes linked to the IgCH locus. J Immunol (1979) 1.43
Statistical analysis of animal cancer chemoprevention experiments. Biometrics (1993) 1.41
Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res (1997) 1.41
A stratified Wilcoxon-type test for trend. Stat Med (1990) 1.40
The future of prognostic factors in outcome prediction for patients with cancer. Cancer (1992) 1.39
Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br Med J (Clin Res Ed) (1988) 1.39
Retinoids in chemoprevention and differentiation therapy. Carcinogenesis (2000) 1.38
Naturally occurring sarcoma virus of the BALB/cCr mouse. J Natl Cancer Inst (1974) 1.38
The use of sequential self-obtained vaginal smears for detecting changes in the vaginal flora. Sex Transm Dis (1997) 1.37
Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol (1999) 1.35
Immune response to levan. III. The capacity to produce anti-inulin antibodies and cross-reactive idiotypes appears late in ontogeny. J Immunol (1979) 1.34
Stopping rules for clinical trials incorporating clinical opinion. Biometrics (1984) 1.33
Receptors for immunoglobulin and complement on mouse leukemias and lymphomas. J Immunol (1972) 1.31
Relationships between socioeconomic status and race-specific cervical cancer incidence in the United States, 1973-1992. J Health Care Poor Underserved (1998) 1.31
Effect of starvation on the tissue composition of the small intestine in the rat. Am J Physiol (1968) 1.31
Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit (1995) 1.30
Randomised comparative studies in the treatment of cancer in the United Kingdom: room for improvement? Lancet (1979) 1.29
Variations in the level of reporting by hospitals to a regional cancer registry. Br J Cancer (1978) 1.29
Randomized, placebo-controlled, double-blind study of low-dose oral interferon-alpha in HIV-1 antibody positive patients. J Acquir Immune Defic Syndr (1992) 1.27
An assay for dopamine-beta-hydroxylase activity in tissues and serum. Experientia (1971) 1.26
Genetic factors controlling anti-sheep erythrocyte antibody response and immunoglobulin synthesis in backcross and F2 progeny of mice genetically selected for "high" or "low" antibody synthesis. J Exp Med (1972) 1.26
Close linkage in genes controlling gamma-A and gamma-G heavy chain structure in BALB/c mice. J Mol Biol (1966) 1.22
Nuclear accumulation of p53 in colorectal adenocarcinoma: prognostic importance differs with race and location of the tumor. Cancer (1998) 1.18
Multivariate analysis of prognostic factors for operable rectal cancer. Lancet (1984) 1.18
Activation and isolation of hamster-specific C-type RNA viruses from tumors induced by cell cultures transformed by chemical carcinogens. Proc Natl Acad Sci U S A (1971) 1.18
Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res (1997) 1.17
The polyp prevention trial I: rationale, design, recruitment, and baseline participant characteristics. Cancer Epidemiol Biomarkers Prev (1996) 1.15
Monitoring clinical trials: conditional or predictive power? Control Clin Trials (1986) 1.14
Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. Carcinogenesis (2000) 1.14
Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer (2000) 1.14
Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. Anticancer Res (1995) 1.14
Regulation of the anti-inulin antibody response by a nonallotype-linked gene. J Exp Med (1980) 1.14
Interplay between design and analysis for behavioral intervention trials with community as the unit of randomization. Am J Epidemiol (1995) 1.13
Isoantibodies specific for myeloma gamma-G and gamma-H immunoglobulins of BALB-c mice. J Mol Biol (1966) 1.13
A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet (2003) 1.13
Intermittent dosing with oltipraz: relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases. Cancer Res (1995) 1.13
Screening of potential chemopreventive agents using biochemical markers of carcinogenesis. Cancer Res (1994) 1.12
Surrogate anatomic/functional sites for evaluating cancer risk: an extension of the field effect. Clin Cancer Res (1999) 1.12
Prevalence of endogenous type-C virus in normal hamster tissues and hamster tumors induced by chemical carcinogens, simian virus 40, and polyoma virus. J Natl Cancer Inst (1974) 1.11
Effect of different types and amounts of fat on the development of mammary tumors in rodents: a review. Cancer Res (1997) 1.11
An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. Br J Cancer (1987) 1.10